Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Nature Reviews Cardiology, Published online: 28 March 2023; doi:10.1038/s41569-023-00849-3Glucagon-like peptide 1 (GLP1) receptor agonists reduce the rate of major adverse cardiovascular events in people with type 2 diabetes mellitus. In this Review, Ussher and Drucker discuss the possible mechanisms of cardiovascular benefit of GLP1 receptor agonists and highlight the novel GLP1-based multi-agonists currently in development.
Source: Nature Reviews Cardiology - Category: Cardiology Authors: John R. Ussher Daniel J. Drucker Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Heart